Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...
Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...
Zacks Investment Research on MSN4d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCCBristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...
Medical Device Network on MSN8d
Foresight announces trial launch for cHL treatment with ctDNA-based MRD testForesight Diagnostics and the University of Washington School of Medicine and Fred Hutch Cancer Center have announced the ...
RELATIVITY-098 is a randomized Phase 3, double-blind study evaluating adjuvant immunotherapy with Opdualag, the fixed-dose combination of nivolumab and relatlimab, compared to Opdivo monotherapy ...
In a study of patients with advanced melanoma, the prevalence of cutaneous immune–related adverse events (cirAEs) associated with nivolumab/relatlimab combination therapy was 21.5%, with rash ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback